Targeted Multi-Omics strategies enhance Bioanalytical workflows in identifying, and validating biomarkers used to define “Mode of Action” and “Off Target Effects” in drug development.

We will discuss development of workflows utilizing Multi-omic mass spectrometry technologies to help elucidate mechanisms of action in Bioanalytical research associated with therapeutic off target effects related to dose response, specifically looking at toxicity. Utilizing targeted approaches, we can demonstrate the complimentary advantages of using the increased sensitivity, precision, linearity, and ease of annotation of QQQ MS with large panels of biomarker targets as we study the mode of action involved with L-asparaginase as an anticancer therapeutic and look to understand associated toxicity in relation to dosage levels in a mouse model. We will present work developed in collaboration with Dr. Phil Lorenzi at MD Anderson Cancer Center.